Brief: RG6501 (Opregen) Phase 1/2A Clinical Results Support Potential For Opregen To Slow, Stop Or Reverse Disease Progression In Geographic Atrophy Secondary To Age-Related Macular Degeneration
03/05/2022 13:42
May 3 (Reuters) -
* RG6501 (OPREGEN®) PHASE 1/2A CLINICAL RESULTS SUPPORT THE
POTENTIAL FOR OPREGEN TO SLOW, STOP OR REVERSE DISEASE
PROGRESSION IN GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED
MACULAR DEGENERATION
Source text for Eikon: ID:nBwbqKQTca
Further company coverage: LCTX.A
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million